Intermediatemetabolism
RNA Processing: Capping, Splicing, and Polyadenylation
Overview
Eukaryotic genes are transcribed as raw pre-mRNA that cannot be used directly — it must be processed before leaving the nucleus. This guide follows the three essential modifications: the 5' cap that protects and identifies the message, the poly-A tail that controls stability, and splicing, where the spliceosome cuts out introns and joins exons. You will learn how alternative splicing lets one gene produce many proteins, and why these steps — absent in bacteria — give eukaryotes a powerful layer of gene regulation.
Learning objectives
- Describe the three main processing steps: 5' capping, splicing, polyadenylation.
- Explain the roles of snRNPs and the spliceosome in removing introns.
- Explain how alternative splicing generates protein diversity.
- Give the functions of the cap and tail in stability, export, and translation.
Structure and function
| Part | Structure | Function |
|---|---|---|
| 5' cap | Modified guanine nucleotide added to the pre-mRNA's 5' end during transcription. | Protects from degradation, aids nuclear export, and is recognized by ribosomes to start translation. |
| Poly-A tail | String of ~200 adenine nucleotides added to the 3' end after cleavage at the poly-A signal. | Stability timer: its gradual shortening controls mRNA lifespan; also aids export and translation. |
| Intron | Non-coding intervening sequence transcribed but removed before translation. | Excised by the spliceosome; allows exon shuffling and alternative splicing in evolution. |
| Exon | Coding (or UTR) sequence retained in the mature mRNA. | Joined together after intron removal; the expressed segments that reach the ribosome. |
| Spliceosome | Large complex of snRNPs (small nuclear ribonucleoproteins) plus proteins. | Recognizes splice sites, cuts introns out as lariats, and ligates exons — the splicing machine. |
| Alternative splicing | Differential inclusion/exclusion of exons producing multiple mRNAs from one gene. | Multiplies proteome diversity: one gene, many protein isoforms, regulated by tissue and condition. |
Diagram: a pre-mRNA drawn left to right with alternating exon blocks (colored) and intron lines (gray), labeled 5' and 3'. Three modification icons: a cap (hat icon) added at the 5' end, scissors (spliceosome) cutting at intron-exon junctions with introns looping out as lariats, and a poly-A tail (string of A's) at the 3' end. The mature mRNA below shows joined exons + cap + tail exiting through a nuclear pore to a ribosome. A branching inset shows one pre-mRNA yielding three different mature mRNAs (alternative splicing) producing three protein shapes.
Why processing exists: the eukaryotic bargain
Bacteria translate mRNA as it's transcribed — no processing needed. Eukaryotes separate transcription (nucleus) from translation (cytoplasm), and that separation created both the need and the opportunity for processing. The need: eukaryotic genes are split — coding exons interrupted by non-coding introns — so the raw transcript must be edited before it makes sense. The opportunity: each processing step is regulatable, giving the cell multiple control points between gene and protein. Processing is quality control plus regulation in one.
5' cap added → introns spliced out → 3' end cleaved and polyadenylated. Only then is the mRNA exported. Each step is verified; failures are degraded by nuclear surveillance.
The 5' cap and poly-A tail: protection and identity
As transcription begins, a modified guanine (7-methylguanosine) is attached to the 5' end — the cap. At the 3' end, the transcript is cleaved downstream of the AAUAAA signal and poly-A polymerase adds ~200 adenines. Both ends serve triple duty: they protect against exonucleases (extending mRNA lifespan), they license nuclear export (unprocessed RNAs are retained and destroyed), and they promote translation (ribosomes recognize the cap; the tail boosts initiation through loop-forming proteins). The tail is also a clock — it shortens over time, and when it's gone, the message is degraded.
The nuclear export machinery checks for proper cap and tail before letting mRNA through the pore. Processing marks are literally export licenses — quality control enforced at the border.
Splicing: cutting introns, joining exons
The spliceosome — five snRNPs (U1, U2, U4, U5, U6) plus dozens of proteins — assembles on each intron, recognizing the GU at the 5' splice site and AG at the 3' site plus a branch-point adenine. In two transesterification steps, the intron is cut out as a lariat (loop) and the flanking exons are ligated. The chemistry is remarkable: the spliceosome is a ribozyme at heart, with its RNA components catalyzing the cuts — a molecular fossil of the RNA world still working in every human cell.
Alternative splicing: one gene, many proteins
By including or skipping exons differentially, one pre-mRNA can yield multiple mature mRNAs — alternative splicing. A gene with 10 exons can theoretically produce many isoforms; some human genes produce dozens. Regulation is tissue-specific: brain, muscle, and immune cells splice shared genes differently, tailoring proteins to each context. This is a major answer to the 'gene number paradox' — humans have only ~20,000 genes yet make far more proteins, largely through alternative splicing.
Introns enable alternative splicing, harbor regulatory sequences and non-coding RNAs, and facilitate exon shuffling in evolution. 'Junk DNA' was always a misnomer — introns are functional infrastructure.
When splicing goes wrong
Splicing errors cause disease: mutations at splice sites produce mis-spliced mRNAs encoding broken proteins — implicated in forms of beta-thalassemia, spinal muscular atrophy, and many cancers. The cell defends itself with surveillance: nonsense-mediated decay detects mRNAs with premature stop codons (often from splicing errors) and destroys them before they make truncated proteins. Therapies are emerging that correct splicing — antisense molecules that mask faulty splice sites, already in clinical use for spinal muscular atrophy.
Drugs that redirect splicing (splice-switching oligonucleotides) treat disease by fixing the processing rather than the gene — a therapeutic layer that exists only because eukaryotes process their RNA.
Key points
- Eukaryotic pre-mRNA needs 5' capping, intron splicing, and 3' polyadenylation before export.
- The cap and tail protect against degradation, license nuclear export, and promote translation.
- The spliceosome (snRNPs U1, U2, U4, U5, U6) removes introns as lariats and ligates exons via ribozyme chemistry.
- Alternative splicing produces multiple protein isoforms from one gene — key to proteome diversity.
- Splicing errors cause diseases (beta-thalassemia, SMA); surveillance (nonsense-mediated decay) and splice-correcting drugs counter them.
Common misconceptions
✓ Truth: Introns enable alternative splicing, contain regulatory elements and non-coding RNAs, and allow exon shuffling during evolution. Removing them would cripple eukaryotic gene regulation — they're infrastructure, not junk.
✓ Truth: Alternative splicing lets one gene produce many protein isoforms by different exon combinations. Humans make far more proteins than our ~20,000 genes — splicing is a major reason why.
✓ Truth: Bacterial mRNA is typically used as-transcribed — no cap, no splicing (their genes lack introns), no poly-A tail for stability. Processing is a eukaryotic innovation tied to the nucleus and split genes.
Practice questions
Q1. The spliceosome removes introns by recognizing:
- The 5' cap and poly-A tail
- Conserved GU/AG splice sites and a branch-point adenine
- The Shine-Dalgarno sequence
- Promoter TATA boxes
snRNPs base-pair with the GU at the intron's 5' splice site, the AG at the 3' site, and the internal branch point, positioning the catalytic core for the two cutting steps. Cap/tail, Shine-Dalgarno (bacterial translation), and TATA boxes serve other processes.
Q2. Alternative splicing increases protein diversity by:
- Mutating exons randomly
- Producing multiple mRNAs with different exon combinations from one pre-mRNA
- Duplicating entire genes
- Adding extra chromosomes
Differential exon inclusion/skipping generates distinct mature mRNAs — and thus distinct protein isoforms — from a single gene, regulated by tissue and condition. No mutation or duplication is involved.
Q3. The 5' cap functions in all of the following EXCEPT:
- Protecting mRNA from exonuclease degradation
- Promoting translation initiation
- Aiding nuclear export
- Coding for amino acids
The cap (7-methylguanosine) protects, licenses export, and recruits ribosomes — but it is not translated; it's a structural modification at the very 5' end, upstream of the coding sequence.
Click a question to reveal the answer and explanation.
Frequently asked questions
Why does the cell bother with introns if they just get removed?
Introns pay for themselves: they enable alternative splicing (multiple proteins per gene), harbor regulatory sequences and functional RNAs, and let evolution shuffle exons into new combinations. The splicing cost buys regulatory and evolutionary flexibility that intron-less genomes lack.
How does the spliceosome know where to cut?
It recognizes conserved sequence signals: GU at the intron's 5' end, AG at the 3' end, and a branch-point adenine inside. snRNPs base-pair with these signals to position the catalytic core precisely — mutations in these signals cause the mis-splicing behind several genetic diseases.
What happens to mRNA that fails processing?
Nuclear surveillance destroys it. Uncapped, unspliced, or mis-spliced transcripts are retained in the nucleus and degraded by exonucleases; nonsense-mediated decay catches exported mRNAs with premature stops. The cell would rather waste a transcript than translate a broken one.
How does alternative splicing help explain human complexity with only ~20,000 genes?
Each gene can encode multiple protein isoforms through different exon combinations, and splicing patterns differ by tissue — brain cells splice shared genes differently than muscle cells. The proteome's diversity comes substantially from combinatorial splicing, not from gene count.